412 related articles for article (PubMed ID: 31142474)
1. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis.
Finzel S; Kraus S; Figueiredo CP; Regensburger A; Kocijan R; Rech J; Schett G
Ann Rheum Dis; 2019 Sep; 78(9):1186-1191. PubMed ID: 31142474
[TBL] [Abstract][Full Text] [Related]
2. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study.
Døhn UM; Ejbjerg B; Boonen A; Hetland ML; Hansen MS; Knudsen LS; Hansen A; Madsen OR; Hasselquist M; Møller JM; Ostergaard M
Ann Rheum Dis; 2011 Feb; 70(2):252-8. PubMed ID: 20980282
[TBL] [Abstract][Full Text] [Related]
3. Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.
Kaeley GS; Nishio MJ; Goyal JR; MacCarter DK; Wells AF; Chen S; Kupper H; Kalabic J
Arthritis Rheumatol; 2016 Nov; 68(11):2584-2592. PubMed ID: 27214046
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
Soubrier M; Puéchal X; Sibilia J; Mariette X; Meyer O; Combe B; Flipo RM; Mulleman D; Berenbaum F; Zarnitsky C; Schaeverbeke T; Fardellone P; Dougados M
Rheumatology (Oxford); 2009 Nov; 48(11):1429-34. PubMed ID: 19741011
[TBL] [Abstract][Full Text] [Related]
5. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
[TBL] [Abstract][Full Text] [Related]
6. Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).
Shimizu T; Choi HJ; Heilmeier U; Tanaka M; Burghardt AJ; Gong J; Chanchek N; Link TM; Graf J; Imboden JB; Li X
Arthritis Res Ther; 2017 Oct; 19(1):222. PubMed ID: 28978352
[TBL] [Abstract][Full Text] [Related]
7. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.
Emery P; Smolen JS; Ganguli A; Meerwein S; Bao Y; Kupper H; Chen N; Kavanaugh A
Rheumatology (Oxford); 2016 Aug; 55(8):1458-65. PubMed ID: 27114561
[TBL] [Abstract][Full Text] [Related]
8. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate.
Smolen JS; van der Heijde DM; Keystone EC; van Vollenhoven RF; Goldring MB; Guérette B; Cifaldi MA; Chen N; Liu S; Landewé RB
Ann Rheum Dis; 2013 Jul; 72(7):1156-62. PubMed ID: 22915617
[TBL] [Abstract][Full Text] [Related]
9. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
Emery P; Genovese MC; van Vollenhoven R; Sharp JT; Patra K; Sasso EH
J Rheumatol; 2009 Jul; 36(7):1429-41. PubMed ID: 19369462
[TBL] [Abstract][Full Text] [Related]
10. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
Burmester GR; Lin Y; Patel R; van Adelsberg J; Mangan EK; Graham NM; van Hoogstraten H; Bauer D; Ignacio Vargas J; Lee EB
Ann Rheum Dis; 2017 May; 76(5):840-847. PubMed ID: 27856432
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
[TBL] [Abstract][Full Text] [Related]
13. Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.
Kimura N; Suzuki K; Takeuchi T
Mod Rheumatol; 2016 Sep; 26(5):676-80. PubMed ID: 26708943
[TBL] [Abstract][Full Text] [Related]
14. Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.
Ormseth MJ; Yancey PG; Solus JF; Bridges SL; Curtis JR; Linton MF; Fazio S; Davies SS; Roberts LJ; Vickers KC; Kon V; Michael Stein C;
Arthritis Rheumatol; 2016 Sep; 68(9):2099-105. PubMed ID: 26991245
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
Takeuchi T; Yamanaka H; Ishiguro N; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
Ann Rheum Dis; 2014 Mar; 73(3):536-43. PubMed ID: 23316080
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
Smolen JS; Avila JC; Aletaha D
Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
Hirata S; Saito K; Kubo S; Fukuyo S; Mizuno Y; Iwata S; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
Arthritis Res Ther; 2013 Sep; 15(5):R135. PubMed ID: 24286472
[TBL] [Abstract][Full Text] [Related]
18. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice.
Kaneko A; Hirano Y; Fujibayashi T; Hattori Y; Terabe K; Kojima T; Ishiguro N
Mod Rheumatol; 2013 May; 23(3):466-77. PubMed ID: 22895833
[TBL] [Abstract][Full Text] [Related]
19. Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis.
Behrens F; Koehm M; Schwaneck EC; Schmalzing M; Wittig BM; Gnann H; Greger G; Tony HP; Burkhardt H
Scand J Rheumatol; 2019 Sep; 48(5):375-382. PubMed ID: 31311386
[No Abstract] [Full Text] [Related]
20. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
van der Heijde D; Breedveld FC; Kavanaugh A; Keystone EC; Landewé R; Patra K; Pangan AL
J Rheumatol; 2010 Nov; 37(11):2237-46. PubMed ID: 20889601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
